Citation

Narayanaswami V, Drake LR, Brooks AF, Meyer JH, Houle S, Kilbourn MR, Scott PJH, Vasdev N. ACS Chem. Neurosci. 2019; 10(4): 1867-1871.

Copyright

(Copyright © 2019, American Chemical Society)

DOI

10.1021/acschemneuro.9b00081

PMID

30789704

PMCID

PMC7568444

Abstract

In this Viewpoint, we highlight the history of positron emission tomography (PET) radiotracer development to quantify changes in monoamine oxidase (MAO)-A and -B enzyme expression or activity. MAO-A and MAO-B are critical for understanding monoaminergic pathways in psychiatric addiction disorders, and more recently in neurodegenerative disorders with MAO-B expression in astrogliosis. Unique radiochemical innovations have been shown for neuroimaging of MAOs including the clinical translation of irreversible propargylamine-based suicide inhibitors, application of deuterium-substitution to slow down metabolism, development of trapped metabolite imaging agents, and unique 11C-carbonylation chemistry toward novel high-affinity reversibly binding inhibitors.

Language: en

Keywords

Humans; Neuroimaging; Brain; PET; Positron-Emission Tomography; Radiopharmaceuticals; Monoamine Oxidase; Drug Development; carbon-11; fluorine-18; MAO-B; MAO-A; Monoamine oxidase